Daily11h
USFDA grants priority review to AstraZeneca-Daiichi Sankyo Enhertu for HER2-low, HER2 Ultralow Breast Cancer
AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...
Cure Today23m
FDA Grants Priority Review to Enhertu for HER2-Low and -Ultralow Breast Cancer
The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...
FiercePharma6d
Fierce Pharma Asia—Daiichi, AZ's ADC setback; Fosun, Kite JV's separation; Yuhan's busy week
AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...
EuropaWire1d
AstraZeneca and Daiichi Sankyo’s Enhertu Receives Priority Review for HER2-Low and Ultralow Breast Cancer Patients Pre-Chemotherapy
AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for trea ...
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A ...
EuropaWire1d
Tag Archives: Ultralow
(IN BRIEF) AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for treating patients with unresectable or ...
Investing5d
Analyst praises Daiichi Sankyo stock for Enhertu's performance in pre-treated HER2+ solid tumors
On Friday, Bernstein SocGen Group maintained its Outperform rating on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY), with a steady price target of JPY6,400.00. The firm's outlook remains ...
TOP NEWS: AstraZeneca and Daiichi hail Enhertu priority review in US
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Tuesday said their cancer drug Enhertu received a priority review by the Food & Drug Administration in the US for some forms of breast ...
Le Lézard6d
Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
For EU media only Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced final 2-year follow-up data from the German cohort of the multinational, European observational MILOS study.1 The ...
Investing5d
Analyst praises Daiichi Sankyo stock for Enhertu's performance in pre-treated HER2+ solid tumors
On Friday, Bernstein SocGen Group maintained its Outperform rating on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY), with a steady price target of JPY6,400.00. The firm's outlook remains ...
Investing1d
Daiichi Sankyo Co Ltd ADR (DSNKY)
On Tuesday, Jefferies maintained a Buy rating on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) with a JPY6,600.00 price target. The endorsement follows Daiichi Sankyo's ...
Wall Street Journal1d
Daiichi Sankyo Co. Ltd.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...